BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III Head-to-Head APSEN Trial for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shots:
- The P-III head-to-head APSEN trial involves assessing Brukinsa (160 mg- PO- bid) vs ibrutinib (420 mg- PO- qd) in 652 patients with r/r CLL or SLL- until disease progression or unacceptable toxicity
- The interim analysis of the trial met its 1EP & pre-specified 2EPs i.e superior ORR & lower risk of atrial fibrillation or flutter respectively. PFS showed an early trend favoring Brukinsa
- BeiGene plans to consult with global regulatory authorities and present the data at an upcoming major medical conference. The ongoing study with pre-specified endpoints of ORR and PFS will be further evaluated at the planned final analysis expected in 2022
Ref: Business Wire | Image: Yicai Global
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com